After Phase III Failure, BioDelivery Plans New Pivotal Pain Trial For Its Buprenorphine
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong placebo effect for pain reduction in opioid-naive patients dampened overall results for the BEMA-buprenorphine product, says company.